Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:7/29/2008

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company's lead product candidate.

* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard's clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled "Designing A Pivotal Program with an Eye Towards Approval." During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.

* BMO Capital Markets' 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

A live audio webcast of each Poniard presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
2. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
3. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
10. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office ... as one of three finalists for the European Inventor Award 2016 in the category ... will be announced at a ceremony in Lisbon on June 9th. , The human ...
(Date:4/26/2016)... MD (PRWEB) , ... April 26, 2016 , ... ... a $1.8M Series A round of financing. Healthy investor interest drove significant oversubscription ... portfolio of generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
Breaking Biology News(10 mins):